EUVIMEDEUVIMED entdecken
Crossref

Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria

Zeynep Keskinkaya, Özge Kaya, Selda Işık Mermutlu, Zerrin Öğretmen

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000538291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Zeynep Keskinkaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Immunoglobulin E. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of patients might complicate the prediction of the treatment outcomes. This study aimed to evaluate the effectiveness and safety of omalizumab in CSU patients, focusing on the factors predicting the response patterns.

Methods

This was a retrospective cross-sectional single-center study investigating CSU patients treated with omalizumab for at least 6 months between September 2015 and February 2023. Patients were evaluated regarding demographics, clinical findings, baseline laboratory parameters, treatment outcomes, and side effects. Early and late responders were defined depending on the time for response, within or after 3 months, respectively.

Results

Among 82 patients, 75 (91.5%) responded to omalizumab during the first 6 months, classified as early (n = 51) and late responders (n = 24). The IgG anti-thyroid peroxidase (anti-TPO)/total IgE ratio was an independent predictor for determining the speed of response (p < 0.05). Of 29 patients who discontinued omalizumab, 19 (65.5%) experienced relapse with a good response to retreatment (n = 18/19, 94.7%). Early responders relapsed more frequently than late responders (77.3% vs. 28.6%) (p < 0.05). Only mild side effects were observed in a minority of patients (n = 8/82, 9.8%).

Conclusion

Omalizumab is an effective and safe treatment in CSU. The IgG anti-TPO/total IgE ratio seems a valuable tool to predict the early and late responders, the former having a higher possibility of relapse upon drug withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsImmunoglobulin EHumansFemaleMaleRetrospective StudiesAdultMiddle AgedCross-Sectional StudiesTreatment OutcomeAutoantibodiesImmunoglobulin G

Stichwörter der Autor:innen

Chronic spontaneous urticariaEarly responderIgG anti-thyroid peroxidaseLate responderOmalizumabTotal IgE

Substanzen

OmalizumabAnti-Allergic AgentsImmunoglobulin EAutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey.

Zitieren

APA

Keskinkaya, Z., Kaya, Ö., Işık Mermutlu, S., & Öğretmen, Z. (2024). Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. https://doi.org/10.1159/000538291

Vancouver

Keskinkaya Z, Kaya Ö, Işık Mermutlu S, Öğretmen Z. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology. 2024. doi:10.1159/000538291

BibTeX
@article{Keskinkaya2024,
  author = {Keskinkaya, Zeynep and Kaya, Özge and Işık Mermutlu, Selda and Öğretmen, Zerrin},
  title = {Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000538291}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche